Aegis Affirms Progenics Pharma (PGNX) at 'Buy'; Solid Relistor Results Fuel Q3 Revenue Gains (VRX)

November 8, 2016 11:57 AM

Aegis Capital affirms Progenics Pharma (Nasdaq: PGNX) at Buy with a price target of $11 following Q3 results issued on ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found